Oxford Cannabinoid Technologies Holdings PLC - London-based clinical stage biopharmaceutical company - Further to announcement on May 8, reaffirms that it is consistent with the declarations that it made following cancellation of its listing on the Official List, it continues to be subject to the obligations placed on it by the Takeover Code. However, notes if the amendments to the Code proposed in the Public Consultation Paper 2024/1 of April are adopted, the Code would cease to apply to the company after a period of three years following the implementation of those amendments.
Current stock price: 0.14 pence
12-month change: down 88%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.